BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 21,050,000 shares, an increase of 5.3% from the June 30th total of 20,000,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the short-interest ratio is presently 10.9 days. Approximately 15.0% of the company’s shares are sold short.
BridgeBio Pharma Stock Performance
BBIO traded up $0.01 during midday trading on Wednesday, reaching $25.95. 1,413,256 shares of the company were exchanged, compared to its average volume of 1,812,965. BridgeBio Pharma has a one year low of $21.62 and a one year high of $44.32. The stock has a market capitalization of $4.86 billion, a P/E ratio of -8.15 and a beta of 1.06. The stock’s 50-day simple moving average is $26.87 and its 200 day simple moving average is $29.52.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.35. The firm had revenue of $211.12 million during the quarter, compared to analyst estimates of $140.06 million. On average, research analysts anticipate that BridgeBio Pharma will post -3.2 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on BridgeBio Pharma
Insiders Place Their Bets
In other news, Director Randal W. Scott sold 1,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the transaction, the director now owns 5,500 shares in the company, valued at approximately $158,620. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 24.66% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Bfsg LLC raised its stake in BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. YHB Investment Advisors Inc. acquired a new position in BridgeBio Pharma in the 1st quarter valued at $34,000. Quarry LP acquired a new position in BridgeBio Pharma in the 4th quarter valued at $50,000. EntryPoint Capital LLC acquired a new position in BridgeBio Pharma in the 1st quarter valued at $117,000. Finally, Assetmark Inc. grew its holdings in BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after buying an additional 935 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
- Five stocks we like better than BridgeBio Pharma
- Buy P&G Now, Before It Sets A New All-Time High
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- The 3 Best Fintech Stocks to Buy Now
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- 5 Top Rated Dividend Stocks to Consider
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.